Hormonal
A specific missense variant in the GIP receptor (GIPR, rs1800437, p.Glu354Gln) is associated with an increased risk of vomiting in patients treated with tirzepatide, but not semaglutide.
If you are taking tirzepatide (Mounjaro/Zepbound), your genetics can influence your risk of vomiting. A specific variant in the GIP receptor (rs1800437) is linked to a higher risk of vomiting. This is specific to tirzepatide because it targets both GLP-1 and GIP receptors. If you experience severe vomiting, discussing your genetic history or considering alternative therapies might be beneficial, as this genetic factor does not affect semaglutide users.
By performing a GWAS in the tirzepatide-treated population alone... we identified an association between the vomiting side effect and GIPR (rs71338792, P = 4.2 × 10−9, odds ratio = 1.84)... The index variant is in near perfect linkage disequilibrium (r2 = 0.99) with a missense variant within GIPR (rs1800437...)
Why this rating
Highly significant p-value, replication in Latino population, strong linkage disequilibrium with a known functional variant, but restricted to one drug type.
Source
Genetic predictors of GLP1 receptor agonist weight loss and side effects
Qiaojuan Jane Su et al. · Nature · 2026
DOI 10.1038/s41586-026-10330-z
More from this paper
- Carrying the T allele of the GLP1R missense variant rs10305420 (p.Pro7Leu) significantly increases weight loss efficacy in patients treated with GLP-1 receptor agonists, adding approximately 0.76 kg of weight loss per allele copy.Good
- Genetic variants in GLP1R that increase weight loss efficacy are also associated with an increased risk of nausea and vomiting, suggesting a link between efficacy and side effects.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →